Literature DB >> 12065683

Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation.

Antonio Marchetti1, Caterina Pellegrini, Fiamma Buttitta, Monica Falleni, Solange Romagnoli, Lara Felicioni, Fabio Barassi, Simona Salvatore, Antonio Chella, Carlo Alberto Angeletti, Massimo Roncalli, Guido Coggi, Silvano Bosari.   

Abstract

Telomerase activity and telomerase reverse transcriptase (hTERT) expression are elevated in human malignancies. We have investigated telomerase activity measured by the telomeric repeat amplification protocol (TRAP) assay and hTERT levels by real-time RT-PCR in stage I non-small-cell lung carcinomas. The purposes of our study included the comparison of these two techniques in the assessment of telomerase function and the evaluation of their prognostic significance. Telomerase activity and hTERT levels were determined in 90 stage I non-small-cell lung carcinoma patients, using TRAP assay and real-time RT-PCR, respectively. Variables were analyzed by the chi(2) and Fisher exact tests. Survival was analyzed by the Kaplan-Meier method. Multivariate analysis was performed with the Cox's proportional hazards model. Telomerase activity was elevated in 60 (67%) carcinomas. hTERT was elevated in 43 (48%) carcinomas. Only 21 (23%) tumors had low telomerase function by both TRAP and hTERT expression levels. Telomerase activity and hTERT were significantly correlated (p = 0.017), although 35 cases displayed discordant results. Both telomerase activity and hTERT levels were significantly associated with poor patient overall and disease-free survival (p = 0.019 and p = 0.018 for TRAP, and p = 0.011 and p = 0.012 for hTERT, respectively). Among the 21 patients with tumors displaying low telomerase function, defined by both TRAP and hTERT expression levels, only one succumbed to the disease (p = 0.0053). Our results suggest that the two techniques used in this study evaluate separate aspects of telomerase function and their combination provides powerful prognostic information in lung cancer patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065683     DOI: 10.1097/01.lab.0000017165.26718.60

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  9 in total

1.  Partial pneumonectomy of telomerase null mice carrying shortened telomeres initiates cell growth arrest resulting in a limited compensatory growth response.

Authors:  Sha-Ron Jackson; Jooeun Lee; Raghava Reddy; Genevieve N Williams; Alexander Kikuchi; Yael Freiberg; David Warburton; Barbara Driscoll
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-04-01       Impact factor: 5.464

2.  The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.

Authors:  Z Chen; J Wang; Y Bai; S Wang; X Yin; J Xiang; X Li; M He; X Zhang; T Wu; P Xu; H Guo
Journal:  Cancer Gene Ther       Date:  2016-12-16       Impact factor: 5.987

3.  Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902.

Authors:  Alice M Boylan; Xiaofei F Wang; Richard Ko; Patricia M Watson; Lin Gu; David Harpole; Raphael Bueno; Rosemary Kelly; Leslie Kohman; Robert Kratzke
Journal:  J Thorac Cardiovasc Surg       Date:  2012-09-29       Impact factor: 5.209

4.  hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors.

Authors:  Xing Fan; Yunyue Wang; John Kratz; Dan J Brat; Yves Robitaille; Albert Moghrabi; Elizabeth J Perlman; Chi V Dang; Peter C Burger; Charles G Eberhart
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

5.  Quantification of alternative splicing variants of human telomerase reverse transcriptase and correlations with telomerase activity in lung cancer.

Authors:  Yan Liu; Bing-quan Wu; Hao-hao Zhong; Xin-xia Tian; Wei-gang Fang
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

6.  Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer.

Authors:  C-Q Zhu; J-C Cutz; N Liu; D Lau; F A Shepherd; J A Squire; M-S Tsao
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

7.  Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.

Authors:  Mark Barszczyk; Pawel Buczkowicz; Pedro Castelo-Branco; Stephen C Mack; Vijay Ramaswamy; Joshua Mangerel; Sameer Agnihotri; Marc Remke; Brian Golbourn; Sanja Pajovic; Cynthia Elizabeth; Man Yu; Betty Luu; Andrew Morrison; Jennifer Adamski; Kathleen Nethery-Brokx; Xiao-Nan Li; Timothy Van Meter; Peter B Dirks; James T Rutka; Michael D Taylor; Uri Tabori; Cynthia Hawkins
Journal:  Acta Neuropathol       Date:  2014-08-06       Impact factor: 17.088

Review 8.  The prognostic significance of hTERT overexpression in cancers: A systematic review and meta-analysis.

Authors:  Kai Wang; Rui-Ling Wang; Jian-Jun Liu; Ji Zhou; Xue Li; Wen-Wei Hu; Wei-Jian Jiang; Ning-Bo Hao
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

9.  Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours.

Authors:  S Lantuejoul; J C Soria; D Moro-Sibilot; L Morat; S Veyrenc; P Lorimier; P Y Brichon; L Sabatier; C Brambilla; E Brambilla
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.